Acute intravenous synaptamine complex variant KB220™"normalizes" neurological dysregulation in patients during protracted abstinence from alcohol and opiates as observed using quantitative electroencephalographic and genetic analysis for reward polymorphisms: Part 1, pilot study with 2 case reports

Postgraduate Medicine

Volumn 122, Issue 6, 2010, Pages 188-213

  Miller, David K ^a,b,c   Bowirrat, Abdalla ^d   Manka, Matthew ^a   Miller, Merlene ^a,b,c   Stokes, Stanley ^b   Manka, Debra ^a   Allen, Cameron ^e   Gant, Charles ^f   Downs, William ^c   Smolen, Andrew ^g   Stevens, Emily ^h   Yeldandi, Swetha ⁱ   Blum, Kenneth ^f,h,i,j  

^a LifeStream Inc   (United States)

^b Bridging the Gaps Treatment Center   (United States)

^c LifeGen Inc   (United States)

^d ZIV MEDICAL CENTER   (Israel)

^e Synaptic Connections Research Institute   (United States)

^f Natl Integrated Health Associates   (United States)

^g UNIVERSITY OF COLORADO   (United States)

^h Path Foundation NY ^*  (United States)

ⁱ UNIVERSITY OF FLORIDA   (United States)

^j UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

more..

Author keywords

Dopaminergic pathways; Intravenous Synaptamine Complex Variant KB220 ; Neurotransmitter genetics; qEEG analysis; Reward deficiency syndrome; Reward genes

Indexed keywords

AMFEBUTAMONE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; CATECHOL METHYLTRANSFERASE; DIAZEPAM; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 4 RECEPTOR; DOPAMINE TRANSPORTER; DOPAMINE TRANSPORTER 1; SEROTONIN TRANSPORTER; SYNAPTAMINE COMPLEX VARIANT KB220; UNCLASSIFIED DRUG; DOPAMINE RECEPTOR STIMULATING AGENT;

ADULT; ALCOHOL ABSTINENCE; ALCOHOLISM; ALLELE; ANGER; ANXIETY; ARTICLE; CANNABIS ADDICTION; CASE REPORT; COCAINE DEPENDENCE; DRUG DETOXIFICATION; EEG ABNORMALITY; ELECTROENCEPHALOGRAPHY; GENE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; HAPPINESS; HEROIN DEPENDENCE; HUMAN; LIMBIC SYSTEM; MAJOR DEPRESSION; MALE; NEUROLOGIC DISEASE; OBSESSION; PILOT STUDY; QUANTITATIVE ANALYSIS; RECEPTOR UPREGULATION; REWARD; REWARD GENE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; VARIABLE NUMBER OF TANDEM REPEAT; WITHDRAWAL SYNDROME; DRUG EFFECT; FOLLOW UP; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME;

ALCOHOLISM; ALLELES; DOPAMINE AGONISTS; ELECTROENCEPHALOGRAPHY; FOLLOW-UP STUDIES; HEROIN DEPENDENCE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; PILOT PROJECTS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, DOPAMINE D2; REWARD; RISK ASSESSMENT; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952055489     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2010.11.2236     Document Type: Article

References (132)

1. Sokhadze TM, Cannon RL, Trudeau DL. EEG biofeedback as a treatment for substance use disorders: review, rating of efficacy, and recommendations for further research. Appl Psychophysiol Biofeedback. 2008;33(1):1-28.
2. Blum K, Wallace JE, Geller I. Synergy of ethanol and putative neurotransmitters: glycine and serine. Science. 1972;176(32):292-294.
3. Blum K, Briggs AH, Trachtenberg MC, Delallo L, Wallace JE. Enkephalinase inhibition: regulation of ethanol intake in genetically predisposed mice. Alcohol. 1987;4(6):449-456.
4. Buchsbaum MS. Evidence, evidence-based medicine, and evidence utility in psychiatry and electrophysiology. Clin EEG Neurosci. 2009;40(2):143-145.
5. Blum K, Trachtenberg MC. Neurogenetic deficits caused by alcoholism: restoration by SAAVE, a neuronutrient intervention adjunct. J Psychoactive Drugs. 1988;20(3):297-313.
6. Cohen MX, Schoene-Bake JC, Elger CE, Weber B. Connectivity-based segregation of the human striatum predicts personality characteristics. Nat Neurosci. 2009;12(1):32-34.
7. Volkow ND, Fowler JS, Wang GJ, Goldstein RZ. Role of dopamine, the frontal cortex and memory circuits in drug addiction: insight from imaging studies. Neurobiol Learn Mem. 2002;78(3):610-624.
8. Kienast T, Siessmeier T, Wrase J, et al. Ratio of dopamine synthesis capacity to D2 receptor availability in ventral striatum correlates with central processing of affective stimuli. Eur J Nucl Med Mol Imaging. 2008;35(6):1147-1158.
9. Underwood MD, Mann JJ, Huang YY, Arango V. Family history of alcoholism is associated with lower 5-HT2A receptor binding in the prefrontal cortex. Alcohol Clin Exp Res. 2008;32(4):593-599.
10. Newton TF, Cook IA, Kalechstein AD, et al. Quantitative EEG abnormalities in recently abstinent methamphetamine dependent individuals. Clin Neurophysiol. 2003;114(3):410-415.
11. Braverman ER, Blum K. Substance use disorder exacerbates brain electrophysiological abnormalities in a psychiatrically-ill population. Clin Electroencephalogr. 1996;27(4 suppl):5-27.
12. Saletu B, Anderer P, Saletu-Zyhlarz GM, Arnold O, Pascual-Marqui RD. Classification and evaluation of the pharmacodynamics of psychotropic drugs by single-lead pharmaco-EEG, EEG mapping and tomography (LORETA). Methods Find Exp Clin Pharmacol. 2002;24(suppl C); 97-120.
13. Finn PR, Justus A. Reduced EEG alpha power in the male and female offspring of alcoholics. Alcohol Clin Exp Res. 1999;23(2):256-262.
14. Kaplan RF, Glueck BC, Hesselbrock MN, Reed HB Jr. Power and coherence analysis of the EEG in hospitalized alcoholics and nonalcoholic controls. J Stud Alcohol. 1985;46(2):122-127.
15. Michael A, Mirza KA, Mukundan CR, Channabasavanna SM. Interhemispheric electroencephalographic coherence as a biological marker in alcoholism. Acta Psychiatr Scand. 1993;87(3):213-217.
16. Winterer G, Enoch MA, White KV, Saylan M, Coppola R, Goldman D. EEG phenotype in alcoholism: increased coherence in the depressive subtype. Acta Psychiatr Scand. 2003;108(1):51-60.
17. de Bruin EA, Stam CJ, Bijl S, Verbaten MN, Kenemans JL. Moderate-to-heavy alcohol intake is associated with differences in synchronization of brain activity during rest and mental rehearsal. Int J Psychophysiol. 2006;60(3):304-314.
18. Struve FA, Straumanis JJ, Patrick G, Price L. Topographic mapping of quantitative EEG variables in chronic heavy marihuana users: empirical findings with psychiatric patients. Clin Electroencephalogr. 1989;20(1):6-23.
19. Struve FA, Manno BR, Kemp P, Patrick G, Manno JE. Acute marijuana (THC) exposure produces a "transient" topographic quantitative EEG profile identical to the "persistent" profile seen in chronic heavy users. Clin Electroencephalogr. 2003;34(2):75-83.
20. Polunina AG, Davydov DM. EEG spectral power and mean frequencies in early heroin abstinence. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(1):73-82.
21. Franken IH, Stam CJ, Hendriks VM, van den Brink W. Electroencephalographic power and coherence analyses suggest altered brain function in abstinent male heroin-dependent patients. Neuropsychobiology. 2004;49(2):105-110.
22. Bauer LO. Predicting relapse to alcohol and drug abuse via quantitative electroencephalography. Neuropsychopharmacology. 2001;25(3):332-340.
23. Prichep LS, Alper KR, Sverdlov L, et al. Outcome related electrophysiological subtypes of cocaine dependence. Clin Electroencephalogr. 2002;33(1):8-20.
24. Alper KR. The EEG and cocaine sensitization: a hypothesis. J Neuropsychiatry Clin Neurosci. 1999;11(2):209-221.
25. Roemer RA, Cornwell A, Dewart D, Jackson P, Ercegovac DV. Quantitative electroencephalographic analyses in cocaine-preferring polysubstance abusers during abstinence. Psychiatry Res. 1995;58(3):247-257.
26. Reid MS, Flammino F, Howard B, Nilsen D, Prichep LS. Topographic imaging of quantitative EEG in response to smoked cocaine self-administration in humans. Neuropsychopharmacology. 2006;31(4):872-884.
27. Venneman S, Leuchter A, Bartzokis G, et al. Variation in neurophysiological function and evidence of quantitative electroencephalogram discordance: predicting cocaine-dependent treatment attrition. J Neuropsychiatry Clin Neurosci. 2006;18(2):208-216.
28. Ceballos NA, Bauer LO, Houston RJ. Recent EEG and ERP findings in substance abusers. Clin EEG Neurosci. 2009;40(2):122-128.
29. Nestor L, Hester R, Garavan H. Increased ventral striatal BOLD activity during non-drug reward anticipation in cannabis users. Neuroimage. 2010;49(1):1133-1143.
30. Bowirrat A, Oscar-Berman M. Relationship between dopaminergic neurotransmission, alcoholism, and reward deficiency syndrome. Am J Med Genet B Neuropsychiatr Genet. 2005;132B(1):29-37.
31. Blum K, Chen TJ, Meshkin B, et al. Manipulation of catechol-O-methyl-transferase (COMT) activity to influence the attenuation of substance seeking behavior, a subtype of Reward Deficiency Syndrome (RDS), is dependent upon gene polymorphisms: a hypothesis. Med Hypotheses. 2007;69(5):1054-1060.
32. Tabakoff B, Saba L, Printz M, et al; WHO/ISBRA Study on State and Trait Markers of Alcoholism. Genetical genomic determinants of alcohol consumption in rats and humans. BMC Biol. 2009;7:70.
33. Hodgkinson CA, Yuan Q, Xu K, et al. Addictions biology: haplotype-based analysis for 130 candidate genes on a single array. Alcohol. 2008;43(5):505-515.
34. Li CY, Mao X, Wei L. Genes and (common) pathways underlying drug addiction. PLoS Comput Biol. 2008;4(1):e2.
35. Blum K, Kozlowski GP. Ethanol and neurotransmitter interactions: a cascade model of reward. In: Ollat H, Parvez S, Parvez H, eds. Alcohol Behav. Utrecht, The Netherlands: VSP Press; 1990:131-149.
36. Comings DE, Blum K. Reward deficiency syndrome: genetic aspects of behavioral disorders. Prog Brain Res. 2000;126:325-341.
37. Noble EP, Blum K, Ritchie T, Montgomery A, Sheridan PJ. Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch Gen Psychiatry. 1991;48(7):648-654.
38. Ritchie T, Noble EP. Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics. Neurochem Res. 2003;28(1):73-82.
39. Blum K, Chen TJ, Downs BW, et al. Neurogenetics of dopaminergic receptor supersensitivity in activation of brain reward circuitry and relapse: proposing "deprivation-amplification relapse therapy" (DART). Postgrad Med. 2009;121(6):176-196.
40. Blum K, Noble EP, Sheridan PJ, et al. Allelic association of human dopamine D2 receptor gene in alcoholism. JAMA. 1990;263(15):2055-2060.
41. Vereczkei A, Sasvári-Székely M, Barta C. The role of genetic variants of the dopaminergic system in heroin dependence [in Hungarian]. Neuropsychopharmacol. 2009:11(2):95-101.
42. Xu K, Lichtermann D, Lipsky RH, et al. Association of specific haplotypes of D2 dopamine receptor gene with vulnerability to heroine dependence in 2 distinct populations. Arch Gen Psychiatry. 2004;61(6):597-606.
43. Blum K, Sheridan PJ, Wood RC, Braverman ER, Chen TJ, Comings DE. Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behaviour. Pharmacogenetics. 1995;5(3):121-141.
44. Blum K, Chen AL, Chen TJ, et al. Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary. Theor Biol Med Model. 2008;5:24.
45. Nair SG, Adams-Deutsch T, Epstein DH, Shaham Y. The neuropharmacology of relapse to food seeking: methodology, main findings, and comparison with relapse to drug seeking. Prog Neurobiol. 2009;89(1):18-45.
46. Hirvonen MM, Laakso A, Någren K, Rinne JO, Pohjalainen T, Hietala J. C957T polymorphism of dopamine D2 receptor gene affects striatal DRD2 in vivo availability by changing the receptor affinity. Synapse. 2009;63(10):907-912.
47. Hill SY, Hoffman EK, Zezza N, et al. Dopaminergic mutations: within-family association and linkage in multiplex alcohol dependence families. Am J Med Genet B Neuropsychiatr Genet. 2008;147B(4):517-526.
48. Li X, Hoffman AF, Peng XQ, Lupica CR, Gardner EL, Xi ZX. Attenuation of basal and cocaine-enhanced locomotion and nucleus accumbens dopamine in cannabinoid CB1-receptor-knockout mice. Psychopharmacology (Berl). 2009;204(1):1-11.
49. Volkow ND, Wang GJ, Kollins SH, et al. Evaluating dopamine reward pathway in ADHD: clinical implications. JAMA. 2009;302(10):1084-1091.
50. Yan QS. Ethanol-induced, nonexocytotic [3H]dopamine release from rat nucleus accumbens slices. Alcohol. 2002;27(2):127-134.
51. Honkanen A, Ahtee L, Korpi ER. Voluntary alcohol drinking selectively accelerates dopamine release in the ventral striatum as reflected by 3-methoxytyramine levels. Brain Res. 1997;774(1-2):207-210.
52. Thanos PK, Taintor NB, Rivera SN, et al. DRD2 gene transfer into the nucleus accumbens core of the alcohol preferring and nonpreferring rats attenuates alcohol drinking. Alcohol Clin Exp Res. 2004;28(5):720-728.
53. Thanos PK, Volkow ND, Freimuth P, et al. Overexpression of dopamine D2 receptors reduces alcohol self-administration. J Neurochem. 2001;78(5):1094-1103.
54. Thanos PK, Rivera SN, Weaver K, et al. Dopamine D2R DNA transfer in dopamine D2 receptor-deficient mice: effects on ethanol drinking. Life Sci. 2005;77(2):130-139.
55. Sanderson SC, Wardle J. Will genetic testing for complex diseases increase motivation to quit smoking? Anticipated reactions in a survey of smokers. Health Educ Behav. 2005;32(5):640-653.
56. Zijlstra F, Booij J, van den Brink W, Franken IH. Striatal dopamine D2 receptor binding and dopamine release during cue-elicited craving in recently abstinent opiate-dependent males. Eur Neuropsychopharmacol. 2008;18(4):262-270.
57. Devoto P, Flore G, Pira L, Diana M, Gessa GL. Co-release of noradrenaline and dopamine in the prefrontal cortex after acute morphine and during morphine withdrawal. Psychopharmacology (Berl). 2002;160(2):220-224.
58. Sanderson SC, Wardle J. Will genetic testing for complex diseases increase motivation to quit smoking? Anticipated reactions in a survey of smokers. Health Educ Behav. 2005;32(5):640-653.
59. Lee J, Ramchandani VA, Hamazaki K, et al. A critical evaluation of influence of ethanol and diet on salsolinol enantiomers in humans and rats. Alcohol Clin Exp Res. 2010;34(2):242-250.
60. Nowak KL, McBride WJ, Lumeng L, Li TK, Murphy JM. Blocking GABA(A) receptors in the anterior ventral tegmental area attenuates ethanol intake of the alcohol-preferring P rat. Psychopharmacology (Berl). 1998;139(1-2):108-116.
61. Blum K, Briggs AH, Trachtenberg MC, Delallo L, Wallace JE. Enkephalinase inhibition: regulation of ethanol intake in genetically predisposed mice. Alcohol. 1987;4(6):449-456.
62. George SR, Roldan L, Lui A, Naranjo CA. Endogenous opioids are involved in the genetically determined high preference for ethanol consumption. Alcohol Clin Exp Res. 1991;15(4):668-672.
63. Maldonado R, Daugé V, Feger J, Roques BP. Chronic blockade of D2 but not D1 dopamine receptors facilitates behavioural responses to endogenous enkephalins, protected by kelatorphan, administered in the accumbens in rats. Neuropharmacology. 1990;29(3):215-223.
64. Downs BW, Chen AL, Chen TJ, et al. Nutrigenomic targeting of carbohydrate craving behavior: can we manage obesity and aberrant craving behaviors with neurochemical pathway manipulation by Immunological Compatible Substances (nutrients) using a Genetic Positioning System (GPS) Map? Med Hypotheses. 2009;73(3):427-434.
65. Blum K, Chen TJ, Downs BW, et al. Synaptamine (SG8839) An amino-acid enkephalinase inhibition nutraceutical improves recovery of alcoholics, a subtype of reward deficiency syndrome (RDS). Trends Appl Sci Res. 2007;2(2):132-138.
66. Blum K, Trachtenberg ML, Cook DW. Neuronutrient effects on weight loss in carbohydrate bingers: an open clinical trial. Curr Ther Res. 1990;43:217-223
67. Blum K, Allison D, Trachtenberg MC, Williams RW, Loeblich LA. Reduction of both drug hunger and withdrawal against advice rate of cocaine abusers in a 30 day inpatient treatment program by the neuronutrient tropamine. Curr Ther Res. 1988;43:1204-1214.
68. Blum K, Trachtenberg MC, Ramsay JC. Improvement of inpatient treatment of the alcoholic as a function of neurotransmitter restoration: a pilot study. Int J Addict. 1988;23(9):991-998.
69. Blum K, Chen TJ, Meshkin B, et al. Genotrim, a DNA-customized nutrigenomic product, targets genetic factors of obesity: hypothesizing a dopamine-glucose correlation demonstrating reward deficiency syndrome (RDS). Med Hypotheses. 2007;68(4):844-852.
70. Blum K, Chen AL, Chen TJ, et al. Putative targeting of dopamine D2 receptor function in reward deficiency syndrome (RDS) by Synaptamine complexTM variant (KB220): clinical trial showing anti-anxiety effects. Gene Ther Mol Biol. 2009;13:214-230.
71. Blum K, Chen AL, Chen TJ, et al. LG839: anti-obesity effects and polymorphic gene correlates of reward deficiency syndrome. Adv Ther. 2008;25(9):894-913.
72. Blum K, Chen TJ, Williams L, et al. A short term pilot open label study of LG839, a customized DNA directed nutraceutical in obesity: exploring nutrigenomics. Gene Ther Mol Biol. 2008;12:371-382.
73. Blum K, Trachtenberg MC, Elliott CE, et al. Enkephalinase inhibition and precursor amino acid loading improves inpatient treatment of alcohol and polydrug abusers: double-blind placebo-controlled study of the nutritional adjunct SAAVE. Alcohol. 1988;5(6):481-493.
74. Blum K, Trachtenberg MC, Ramsay JC. Improvement of inpatient treatment of the alcoholic as a function of neurotransmitter restoration: a pilot study. Int J Addict. 1988;23(9):991-998.
75. Brown RJ, Blum K, Trachtenberg MC. Neurodynamics of relapse prevention: a neuronutrient approach to outpatient DUI offenders. J Psychoactive Drugs. 1990;22(2):173-187.
76. Fisch B, Spehlmann R, eds. EEG Primer: Basic Principals of Digital and Analog EEG. 3rd ed. Elsevier: New York, NY; 2008.
77. Russo S, Kema IP, Bosker F, Haavik J, Korf J. Tryptophan as an evolutionarily conserved signal to brain serotonin: molecular evidence and psychiatric implications. World J Biol Psychiatry. 2009;10(4):258-268.
78. Russell AL, McCarty MF. DL-phenylalanine markedly potentiates opiate analgesia-an example of nutrient/pharmaceutical up-regulation of the endogenous analgesia system. Med Hypotheses. 2000;55(4):283-288.
79. Nuwer MR. Quantitative EEG: I. Techniques and problems of frequency analysis and topographic mapping. J Clin Neurophysiol. 1988;5(1):1-43.
80. Lee SH, Han DH, Oh S, et al. Quantitative electroencephalographic (qEEG) correlates of craving during virtual reality therapy in alcohol-dependent patients. Pharmacol Biochem Behav. 2009;91(3):393-397.
81. Budzynski TH, Budzynski HK, Evans R, Abarbanel A. Introduction to Quantitative EEG and Neurofeedback, Second Edition: Advanced Theory and Applications. Burlington, MA: Academic Press; 2009.
82. Mason BJ, Light JM, Williams LD, Drobes DJ. Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin. Addict Biol. 2009;14(1):73-78.
83. Anchordoquy HC, McGeary C, Liu L, Krauter KS, Smolen A. Genotyping of three candidate genes following whole genome preamplification of DNA collected from buccal cells. Behav Genet. 2003;33(1):73-78.
84. Haberstick BC, Smolen A. Genotyping of three single nucleotide polymorphisms following whole genome preamplification of DNA collected from buccal cells. Behav Genet. 2004;34(5):541-547.
85. Haberstick BC, Lessem JM, Hopfer CJ, et al. Monoamine oxidase A (MAOA) and antisocial behaviors in the presence of childhood and adolescent maltreatment. Am J Med Genet B Neuropsychiatr Genet. 2005;135B(1):59-64.
86. Vandenbergh D J, Perisco AM, Hawkins AL, et al. Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics. 1992;14(4):1104-1106.
87. Van Tol HH, Wu CM, Guan HC, et al. Multiple dopamine D4 receptor variants in the human population. Nature. 1992;358(6382):149-152.
88. Lerman C, Caporaso N, Main D, et al. Depression and self-medication with nicotine: the modifying influence of the dopamine D4 receptor gene. Health Psychol. 1998;17(1):56-62.
89. Sabol SZ, Hu S, Hamer D. A functional polymorphism in the monoamine oxidase A gene promoter. Hum Genet. 1998;103(3):273-279.
90. Caspi A, McClay J, Moffitt TE, et al. Role of genotype in the cycle of violence in maltreated children. Science. 2002;297(5582):851-854.
91. Heils A, Teufel A, Petri S, et al. Allelic variation of human serotonin transporter gene expression. J Neurochem. 1992;66(6):2621-2624.
92. Lesch KP, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996;274(5292):1527-1531.
93. Hu X, Oroszi G, Chun J, et al. An expanded evaluation of the relationship of four alleles to the level of response to alcohol and the alcoholism risk. Alcohol Clin Exp Res. 2005;29(1):8-16.
94. Sander T, Harms H, Dufeu P, et al. Dopamine D4 receptor exon III alleles and variation of novelty seeking in alcoholics. Am J Med Genet. 1997;74(5):483-487.
95. Pohjalainen T, Rinne JO, Nagren K, et al. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry. 1998;3(3):256-260.
96. Männistö PT, Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharm Rev. 1999;51(4):593-628.
97. Akil M, Kolachana BS, Rothmond DA, et al. Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. J Neurosci. 2003;23(6):2008-2013.
98. Fein G, Allen J. EEG spectral changes in treatment-naive, actively drinking alcoholics. Alcohol Clin Exp Res. 2005;29(4):538-546.
99. Engels AS, Heller W, Spielberg JM, et al. Co-occurring anxiety influences patterns of brain activity in depression. Cogn Affect Behav Neurosci. 2010;10(1):141-156.
100. Blum K, Chen TJ, Chen AL, et al. Dopamine D2 Receptor Taq A1 allele predicts treatment compliance of LG839 in a subset analysis of pilot study in the Netherlands. Gene Ther Mol Biol. 2008;12:129-140.
101. Lawford BR, Young RM, Rowell JA, et al. Bromocriptine in the treatment of alcoholics with the D2 dopamine receptor A1 allele. Nat Med. 1995;1(4):337-341.
102. Laakso A, Pohjalainen T, Bergman J, et al. The A1 allele of the human D2 dopamine receptor gene is associated with increased activity of striatal L-amino acid decarboxylase in healthy subjects. Pharmacogenet Genomics. 2005;15(6):387-391.
103. Blum K, Chen TJH, Morse S, et al. Overcoming qEEG abnormalities and reward gene deficits during protracted abstinence in male psychostimulant and polydrug abusers utilizing putative dopamine D2 agonist therapy: part 2. In press. Postgrad Med.
104. Blum K, Chen AL, Braverman ER, et al. Attention-deficit-hyperactivity disorder and reward deficiency syndrome. Neuropsychiatr Dis Treat. 2008;4(5):893-918.
105. Ruiz Martínez M, Gil Extremera B, Maldonado Martín A, Cantero-Hinojosa J, Moreno-Abadía V. Trace elements in drug addicts. Klin Wochenschr. 1990;68(10):507-511.
106. Crüts B, van Etten L, Törnqvist H, et al. Exposure to diesel exhaust induces changes in EEG in human volunteers. Part Fibre Toxicol. 2008;5:4.
107. Kalechstein AD, De la Garza R 2nd, Newton TF, Green MF, Cook IA, Leuchter AF. Quantitative EEG abnormalities are associated with memory impairment in recently abstinent methamphetamine-dependent individuals. J Neuropsychiatry Clin Neurosci. 2009;21(3):254-258.
108. Kraschewski A, Reese J, Anghelescu I, et al. Association of the dopamine D2 receptor gene with alcohol dependence: haplotypes and subgroups of alcoholics as key factors for understanding receptor function. Pharmacogenet Genomics. 2009;19(7):513-527.
109. Prasad P, Ambekar A, Vaswani M. Dopamine D2 receptor polymorphisms and susceptibility to alcohol dependence in Indian males: a preliminary study. BMC Med Genet. 2010;11:24.
110. Serý O, Didden W, Mikes V, Pitelová R, Znojil V, Zvolský P. The association between high-activity COMT allele and alcoholism. Neuro Endocrinol Lett. 2006;27(1-2):231-235.
111. Cao L, Li T, Liu X. Association study of heroin dependence and catechol-O-methyltransferase gene. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2003;20(2):127-130.
112. Horowitz R, Kotler M, Shufman E, et al. Confirmation of an excess of the high enzyme activity COMT val allele in heroin addicts in a family-based haplotype relative risk study. Am J Med Genet. 2000;96(5):599-603.
113. Cao L, Li T, Xu K, Liu X. Association study of heroin-dependence and-287 A/G polymorphism of catechol-O-methyltransferase gene. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2002;19(6):499-501.
114. Cook EH Jr, Stein MA, Krasowski MD, et al. Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet. 1995;56(4):993-998.
115. Lee SS, Lahey BB, Waldman I, et al. Association of dopamine transporter genotype with disruptive behavior disorders in an eight-year longitudinal study of children and adolescents. Am J Med Genet B Neuropsychiatr Genet. 2007;144B(3):310-317.
116. Biederman J, Petty CR, Ten Haagen KS, et al. Effect of candidate gene polymorphisms on the course of attention deficit hyperactivity disorder. Psychiatry Res. 2009;170(2-3):199-203.
117. Grzywacz A, Kucharska-Mazur J, Samochowiec J. Association studies of dopamine D4 receptor gene exon 3 in patients with alcohol dependence [in Polish]. Psychiatr Pol. 2008;42(3):453-461.
118. Kotler M, Cohen H, Segman R, et al. Excess dopamine D4 receptor (D4DR) exon III seven repeat allele in opioid-dependent subjects. Mol Psychiatry. 1997;2(3):251-254.
119. Huang SY, Lin WW, Wan FJ, et al. Monoamine oxidase-A polymorphisms might modify the association between the dopamine D2 receptor gene and alcohol dependence. J Psychiatry Neurosci. 2007;32(3):185-192.
120. Brown BB. Recognition of aspects of consciousness through association with EEG Alpha activity represented by a light signal. Psychophysiology. 1970;6(4):442-452.
121. Stoyva J, Kamiya J. Electrophysiological studies of dreaming as the prototype of a new strategy in the study of consciousness. Psychol Rev. 1968;75(3):192-205.
122. Walsh DH. Interactive effects of alpha feedback and instructional set on subjective states. Psychophysiology. 1973;11(4):235-428.
123. Kasamatsu A, Hirai T. An electroencephalographic study on the zen meditation (Aazen). Folia Psychiatr Neurol Jpn. 1966;20(4):315-336.
124. Michel CM, Lehmann D, Henggeler B, Brandeis D. Localization of the sources of EEG delta, theta, alpha, and beta frequency bands using the FFT dipole approximation. Electroencephalogr Clin Neurophysiol. 1991;82(1):38-44.
125. Green EE, Alyce M. Voluntary control of internal states: psychological and physiological. J Transpersonal Psychology. 1970;2:1-26.
126. Peniston EG, Kulkosky PJ. The Peniston/Kulkosky Brainwave Neurofeedback Therapy for Alcoholism and Posttraumatic Stress Disorders: Medical Psychotherapist Manual. Certificate of Copyright Office. The Library of Congress; 1989:1-25.
127. Peniston EG, Marrinan DA, Deming WA, Kulkosky PJ. EEG alpha-theta brainwave synchronization in Vietnam theater veteran with combat-related posttraumatic stress disorder and alcohol abuse. Medical Psychotherapy. 1993;6:37-50
128. Fahrion ST, Walters ED, Coyne L, Allen T. Alterations in EEG amplitude personality factors and brain electrical mapping after alpha-theta brainwave training: a controlled case study for an alcoholic in recovery. Alcohol Clin Exp Res. 1992;16(3):547-552.
129. Peniston EG, Kulkosky PJ. Alcoholic personality and alpha-theta brainwave training. Medical Psychotherapy. 1990;3:37-55.
130. Cohen MX, Axmacher N, Lenartz D, Elger CE, Sturm V, Schlaepfer TE. Neuroelectric signatures of reward learning and decision-making in the human nucleus accumbens. Neuropsychopharmacology. 2009;34(7):1649-1658.
131. Cohen MX, Krohn-Grimberghe A, Elger CE, Weber B. Dopamine gene predicts the brain's response to dopaminergic drug. Eur J Neurosci. 2007;26(12):3652-3660.
132. Blum K, Stice E, Liu Y, Giordano J, Morse S, Downs BW et al. "Dopamine Resistance" in brain reward circuitry as a function of reward gene polymorphisms in reward deficiency syndrome (RDS): Synaptamine Complex variant [KB220 and KB220Z] induced "dopamine Sensitivity" and anti-craving behavior. To be presented at: Addiction Conference; October 28-30, 2010, Arlington, VA.